Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -2.46%75.67B | 3.16%308.34B | -1.17%73.34B | 5.34%79.66B | 7.01%77.77B | 1.55%77.58B | -1.63%298.89B | 2.12%74.21B | -2.39%75.62B | -6.52%72.67B |
Cost of revenue | -3.09%64.39B | 2.80%262.77B | -1.60%62.29B | 4.66%68.22B | 5.67%65.82B | 2.46%66.44B | -3.11%255.62B | 0.41%63.31B | -3.13%65.18B | -7.77%62.29B |
Gross profit | 1.29%11.28B | 5.30%45.57B | 1.34%11.05B | 9.57%11.44B | 15.09%11.95B | -3.61%11.13B | 8.07%43.27B | 13.39%10.9B | 2.51%10.44B | 1.74%10.39B |
Operating expense | 5.23%6.18B | 11.40%24.56B | -3.32%7.05B | 18.07%5.87B | 13.78%5.76B | 24.56%5.87B | 6.19%22.04B | -2.64%7.29B | 8.15%4.98B | 19.46%5.06B |
Staff costs | ---- | 13.05%8.24B | ---- | ---- | ---- | ---- | 11.10%7.29B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | -1.42%5.34B | ---- | ---- | ---- | ---- | 28.61%5.42B | ---- | ---- | ---- |
-General and administrative expense | ---- | -1.42%5.34B | ---- | ---- | ---- | ---- | 28.61%5.42B | ---- | ---- | ---- |
Other operating expenses | ---- | 17.55%10.97B | ---- | ---- | ---- | ---- | -6.50%9.33B | ---- | ---- | ---- |
Operating profit | -3.10%5.1B | -1.02%21.01B | 10.75%4B | 1.83%5.56B | 16.33%6.19B | -23.02%5.26B | 10.10%21.23B | 69.95%3.61B | -2.13%5.46B | -10.84%5.32B |
Net non-operating interest income (expenses) | 35.61%-85M | -469.57%-170M | -206.67%-32M | -176.92%-36M | -23.08%30M | -1,220.00%-132M | 121.60%46M | 475.00%30M | -30.00%-13M | 3,800.00%39M |
Non-operating interest income | --70M | -28.42%68M | --0 | --23M | -10.00%45M | --0 | 131.71%95M | --45M | --0 | 354.55%50M |
Non-operating interest expense | 107.14%29M | 59.18%78M | 113.33%32M | 30.77%17M | 36.36%15M | 40.00%14M | 36.11%49M | 87.50%15M | 30.00%13M | 10.00%11M |
Total other finance cost | 6.78%126M | --160M | --0 | --42M | --0 | --118M | ---- | ---- | ---- | ---- |
Net investment income | 24.24%205M | 38.68%294M | 0.00%1M | 23.08%128M | 0 | 54.21%165M | 0.47%212M | -80.00%1M | 22.35%104M | 0 |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -3,636.84%-4.7B | 725.00%396M | -1.47B | 215.29%268M | -3.9B | -43.88%133M | -55.14%48M | 0 | 85M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | ||||||||||
Other non-operating income (expenses) | 153.85%7M | -63.04%-75M | -48.48%-49M | 138.10%8M | -21M | -13M | -611.11%-46M | -335.71%-33M | -2,000.00%-21M | |
Income before tax | 278.36%5.23B | -24.19%16.35B | 17.99%4.31B | -24.17%4.2B | 18.57%6.47B | -80.07%1.38B | 10.51%21.57B | 63.23%3.65B | -2.18%5.53B | -10.79%5.45B |
Income tax | 289.47%1.7B | -24.27%5.08B | 16.43%1.3B | -22.20%1.3B | 19.19%2.04B | -80.18%437M | 10.93%6.7B | 60.69%1.12B | 0.91%1.67B | -14.21%1.71B |
Net income | 273.52%3.53B | -24.17%11.28B | 18.63%3.01B | -25.00%2.9B | 18.26%4.43B | -80.03%944M | 10.32%14.87B | 64.44%2.53B | -3.47%3.86B | -9.14%3.75B |
Net income continuous operations | 273.23%3.53B | -24.16%11.28B | 18.67%3.01B | -25.02%2.9B | 18.29%4.43B | -80.02%945M | 10.32%14.87B | 64.37%2.53B | -3.45%3.87B | -9.15%3.75B |
Noncontrolling interests | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to the company | 273.52%3.53B | -24.17%11.28B | 18.63%3.01B | -25.00%2.9B | 18.26%4.43B | -80.03%944M | 10.32%14.87B | 64.44%2.53B | -3.47%3.86B | -9.14%3.75B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 273.52%3.53B | -24.17%11.28B | 18.63%3.01B | -25.00%2.9B | 18.26%4.43B | -80.03%944M | 10.32%14.87B | 64.44%2.53B | -3.47%3.86B | -9.14%3.75B |
Gross dividend payment | ||||||||||
Basic earnings per share | 273.25%114.4 | -24.16%365.89 | 18.63%97.5 | -25.00%94.02 | 18.27%143.72 | -80.02%30.65 | 10.32%482.48 | 64.45%82.19 | -3.47%125.36 | -9.14%121.52 |
Diluted earnings per share | 273.25%114.4 | -24.16%365.89 | 18.63%97.5 | -25.00%94.0157 | 18.27%143.7157 | -80.02%30.65 | 10.32%482.48 | 64.45%82.19 | -3.47%125.3531 | -9.14%121.52 |
Dividend per share | 0 | 3.45%150 | -6.25%75 | 0 | 15.38%75 | 0 | 20.83%145 | 23.08%80 | 0 | 18.18%65 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |